中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 6
Jun.  2010
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2010  >  26(6): 598-601

Effect of medical ozone therapy in the hepatorenal syndrome in patients with chronic severe hepatitis

  • Published Date: 2010-06-20
    Abstract
  • Objective The study is aimed to observe the effects of medical ozone therapy on PRA, AngⅡ, ALD, renal blood flow and renal function in patients with severe chronic hepatitis and to explore the prevention of medical ozone therapy on hepatorenal syndrome.Methods 98 cases with chronic severe hepatitis were randomly divided into ozone therapy group (50 cases) and control group (48 cases) .The patients in the treatment group were treated with medical ozone plus the same basic medical treatments used for the control group.100 ml venous blood was drawn from each patient, and was mixed with 100 ml (35 μg/ml) medical ozone and then was returned the blood to the patient intravenously, once every other day for 20 days.Renal blood flow of the patients were determined by American GELOGIO-7 color Doppler ultrasonic examination.The levels of PRA, AngII and ALD were detected by RIA.Results The levels of PRA, AngⅡ, ALD in the treatment group were decreased significantly compared with those before treatment (P < 0.01) , also lower than those of control group after treatment (P < 0.01) .Renal blood flow was increased compared to before the treatment and also higher than that of the control group after the treatment (P < 0.01) .Renal damage (hepatorenal syndrome) happened in the treatment group was less than that in the control group (P < 0.01) .The survival rate in the treatment group was higher than that in the control group.Conclusion Combination therapy of medical ozone could decrease levels of PRA, AII and ALD significantly, increase renal blood flow, prevent hepatorenal syndrome and improve the survival rate of patients with chronic severe hepatitis.

     

    • FullText(HTML)
    • References(17)
  • [1]Chen J, Han JH, Liu C, et al.Short-term entecavir therapy of chronic severe hepatitis B[J].Hepatobiliary Pancreat Dis Int, 2009, 8 (3) ∶261-266.
    [2] 周霞秋.肝衰竭的药物治疗[J].世界感染杂志, 2009, 9 (5) ∶281-285.
    [3]Matsui Y, Sugawara Y, Yamashiki N, et al.Living donor liver transplantation for fulminant hepatic failure[J].Hepatol Res, 2008, 38 (10) ∶987-996.
    [4]中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) ∶324-329.
    [5]顾锡炳, 华忠, 王栋, 等.医用三氧与人工肝血浆置换治疗重型肝炎的对比研究[J].临床肝胆病杂志, 2008, 24 (2) ∶118-119.
    [6]王小丛, 孙琦, 于国良, 等.彩色多普勒对肝肾综合症及肝硬化失代偿期肾动脉血流动力学的研究[J].临床肝胆病杂志, 1996, 12 (4) ∶212-213.
    [7]梁春香, 由丽霞, 张青, 等.正常成人肾内动脉血流动力学的彩色多普勒研究[J].中国超声医学杂志, 1995, 11 (2) ∶103-106.
    [8]顾锡炳, 刘霞英, 徐月琴, 等.不限钠饮食与限钠饮食对肝硬化患者肾血流量及腹水消退的影响[J].中华消化杂志, 2008, 28 (1) ∶61-62.
    [9]曹红, 周敏, 周苗兰.三氧治疗慢性重型肝炎临床疗效观察[J].中国微循环, 2007, 11 (4) ∶269-270.
    [10]Wentworth P Jr, Mcdunn JE, Wentworth AD, et al.Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation[J].Science, 2002, 298 (13) ∶2195-2199.
    [11]Bocci V.Ozonization of blood for the therapy of viral diseases and immunodeficiencies.A hypothesis[J].Med Hypotheses, 1992, 39 (1) ∶30-34.
    [12] 郭亚兵, 周福元.医用臭氧治疗慢性乙型病毒性肝炎的初步认识[J].第一军医大学学报, 2005, 25 (增刊) ∶150-151.
    [13]熊号峰, 贾继东.肝衰竭合并肝肾综合症的研究进展[J].传染病信息, 2009, 22 (5) ∶269-272.
    [14]Rivolta R, Maggi A, Cazzaniga M, et al.Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites[J].Hepatology, 1998, 28 (5) ∶1235-1240.
    [15]Guevara M, Bru C, Gines P, et al.Increased cerebrovascular resistance in cirrhotic patients with ascites[J].Hepatology, 1998, 28 (1) ∶39-44.
    [16]刘建军, 智红.肝硬化腹水限钠治疗的弊端及其对策[J].新医学, 2003, 34 (2) ∶123.
    [17]Angeli P, Merkel C.Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis[J].J Hepatol, 2008, 48 (suppl1) ∶s93-s103.
    • Relative Articles

  • Relative Articles

    [1]Jiaqi LIANG, Wen LIU. Integrated traditional Chinese and Western medicine diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2022, 38(9): 1974-1979. doi: 10.3969/j.issn.1001-5256.2022.09.005
    [2]Lihong YANG, Jinhui YANG. Mechanism and treatment of portal-systemic circulatory imbalance in hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2021, 37(12): 2770-2773. doi: 10.3969/j.issn.1001-5256.2021.12.006
    [3]LI Yan, LU LunGen. Emphasis on the basic and clinical research on hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2401-2405. doi: 10.3969/j.issn.1001-5256.2020.11.001
    [4]SONG JingRu, SUN MingYu. Research advances in integrated traditional Chinese and Western medicine therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2561-2564. doi: 10.3969/j.issn.1001-5256.2020.11.037
    [5]LI XiaoYun, HUA Jing. Treatment of hepatorenal syndrome:Vasoconstriction or vasodilation?[J]. Journal of Clinical Hepatology, 2020, 36(11): 2419-2422. doi: 10.3969/j.issn.1001-5256.2020.11.005
    [6]CHEN WenJi, LIANG Wei, ZHOU YongJian. Acute kidney injury and hepatorenal syndrome in end-stage liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2423-2428. doi: 10.3969/j.issn.1001-5256.2020.11.006
    [7]LI Yan, LU LunGen, CAI XiaoBo. Advances in the treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2415-2418. doi: 10.3969/j.issn.1001-5256.2020.11.004
    [8]LIAO XianHua, YE JunZhao, ZHONG BiHui. Pathogenesis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2406-2410. doi: 10.3969/j.issn.1001-5256.2020.11.002
    [9]Chen LanLan, Han Wen, Liu JingJing, Hu Dan, He WeiWei. Research advances in the biomarkers for the early diagnosis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2018, 34(11): 2448-2452. doi: 10.3969/j.issn.1001-5256.2018.11.040
    [10]Chen Li, Mei Yong, Yang YiBin, Cao MingYan. Research advances in renal replacement therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2016, 32(3): 605-608. doi: 10.3969/j.issn.1001-5256.2016.03.046
    [11]Chen ShengPeng, He WeiPing, Li YuFang, Wu JiJun. Clinical analysis of misdiagnosis and missed diagnosis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(4): 444-445.
    [12]Wang JiYao. The difficulties in diagnosis and treatment of hepatorenal syndrome-raised by clinical cases[J]. Journal of Clinical Hepatology, 2011, 27(10): 1019-1021.
    [13]Xu XiaoYuan, Zheng YingYing. Hepatorenal syndrome-vasoconstrictor or vasodilator?[J]. Journal of Clinical Hepatology, 2011, 27(8): 801-803+817.
    [14]Gao BaoXiu, He Yong, Li GuiXing, Nie Xin, Luo TongXing, Song HaoLan. Analysis of relationship of chronic severe hepatitis with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(7): 749-751.
    [15]Xie YongPeng, Hou Yue, Zang XiuXian, Chu Zhe. The development of treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(5): 558-561.
    [16]Zheng XiaoLi, Wang LiangZhi. Current diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(1): 107-109.
    [17]Fu Qiang, Tang TongYu. Advance in research of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2010, 26(5): 557-560.
    • Supplements(0)
    • Cited By
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-042024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-0305101520
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 3.5 %FULLTEXT: 3.5 %META: 94.6 %META: 94.6 %PDF: 1.9 %PDF: 1.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 3.8 %其他: 3.8 %其他: 1.1 %其他: 1.1 %上海: 0.8 %上海: 0.8 %北京: 11.7 %北京: 11.7 %北海: 0.3 %北海: 0.3 %华盛顿州: 0.3 %华盛顿州: 0.3 %南宁: 0.5 %南宁: 0.5 %合肥: 0.3 %合肥: 0.3 %吉林: 0.5 %吉林: 0.5 %呼和浩特: 1.6 %呼和浩特: 1.6 %大阪: 1.6 %大阪: 1.6 %宿迁: 0.8 %宿迁: 0.8 %崇左: 0.3 %崇左: 0.3 %布劳利: 0.3 %布劳利: 0.3 %常州: 0.3 %常州: 0.3 %廊坊: 0.3 %廊坊: 0.3 %张家口: 4.3 %张家口: 4.3 %恩施: 0.3 %恩施: 0.3 %扬州: 0.3 %扬州: 0.3 %新乡: 2.2 %新乡: 2.2 %杭州: 1.1 %杭州: 1.1 %武汉: 0.3 %武汉: 0.3 %淮安: 0.5 %淮安: 0.5 %温州: 0.3 %温州: 0.3 %湖州: 0.3 %湖州: 0.3 %玉林: 1.1 %玉林: 1.1 %石家庄: 0.3 %石家庄: 0.3 %红河: 0.3 %红河: 0.3 %芒廷维尤: 23.3 %芒廷维尤: 23.3 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.3 %苏州: 0.3 %莫斯科: 0.3 %莫斯科: 0.3 %西宁: 30.1 %西宁: 30.1 %贵港: 1.6 %贵港: 1.6 %连云港: 0.5 %连云港: 0.5 %郑州: 6.8 %郑州: 6.8 %重庆: 0.3 %重庆: 0.3 %长沙: 0.3 %长沙: 0.3 %阜阳: 0.3 %阜阳: 0.3 %青岛: 0.3 %青岛: 0.3 %黔南: 0.3 %黔南: 0.3 %其他其他上海北京北海华盛顿州南宁合肥吉林呼和浩特大阪宿迁崇左布劳利常州廊坊张家口恩施扬州新乡杭州武汉淮安温州湖州玉林石家庄红河芒廷维尤芝加哥苏州莫斯科西宁贵港连云港郑州重庆长沙阜阳青岛黔南

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3902) PDF downloads(815) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2941]YesterdayPV[5274]TodayIP[1509]TodayPV[2255]Online[111]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return